ImmunogenX to Make Highlighted Presentations at DDW 2017

Work recognized as outstanding by leading authorities

On the basis of newly released post hoc analyses of the recent ALV003-1221 trial for latiglutenase (CeliAction® Study), ImmunogenX has been selected to give a Lecture Presentation at the 2017 Digestive Disease Week (DDW) Conference being held in Chicago, IL on May 6-9. DDW is the first and foremost gastrointestinal event in the world. Dr. Jack Syage, CEO will deliver a talk entitled:

“Oral Latiglutenase Improves Chronic Symptoms in Seropositive Celiac Disease Patients”

which will take place on Tuesday May 9th at 9:00 am at McCormick Place (Rm S106) and will focus on the new and exciting symptom improvement data observed for seropositive celiac disease (CD) patients and the implications for future trials. We are also excited that another presentation entitled:

“Celiac Disease Patients Practicing a Gluten-Free Diet Still Consume Unsafe Levels of Gluten”

has been selected to be featured on a poster tour conducted by tour leader and key clinician and opinion leader Dr. Joseph Murray of the Mayo Clinic on Sunday May 7th at 12:00 pm. Once again our work is being recognized as outstanding in “interest and quality” by leading authorities and peers.

Dr. Jack Syage, CEO remarks “The prospects for latiglutenase to treat CD patients has never looked brighter given the recent superlative post hoc results for symptom relief in seropositive patients. It is gratifying to see this work get recognized and appreciated by illustrious peers in the field.”

In another development the well-respected CD advocacy organization Beyond Celiac recently released an article that provided a balanced view of the recent ALV003-1221 trial. In particular the article noted the statistically and clinically significant symptom benefits observed for the subpopulation of patients who are seropositive, which comprised greater than 40% of this Phase 2b trial. In that article Dr. Peter H.R. Green, a study investigator and Director of the Celiac Disease Center at Columbia University, is quoted “…we have since discovered that people with symptoms and elevated celiac disease antibodies did have a significant benefit….We are thrilled with that because it gives the medicine an ongoing opportunity to get out there to help patients.”

About ImmunogenX

ImmunogenX (a subsidiary of Immunogenics LLC) is a clinical-stage biotherapeutics company founded in 2013 and is supported by a team of world-renowned clinicians, scientists and advisors in celiac disease research. The company is developing Latiglutenase (formerly ALV003) for celiac disease therapy. ImmunogenX is also developing a minimally-invasive diagnostic tool for celiac disease management (CypCei™) based on a clinically relevant metabolic marker compound that can assess the state of recovery of a celiac patient adhering to a gluten-free diet or other treatment. For food safety, ImmunogenX is pioneering advanced mass spectrometry methods to identify and measure physiologically relevant gluten peptide sequences found in wheat, barley, and rye.

www.immunogenx.com

For further information please contact

Matthew Dickason, COO
949 679-0900
mdickason@immunogenx.com